Regulus Therapeutics this week announced that AstraZeneca has selected an undisclosed oncology target under the companies' ongoing partnership to develop microRNA-targeting drugs for oncology and cardiovascular and metabolic diseases.
The companies began working together last year, agreeing to co-develop and –commercialize miRNA drugs against three exclusive targets, including potentially miRNA-33 in atherosclerosis (GSN 8/16/2012).
Regulus received $28 million upfront, which included an equity investment, and stands to be paid milestones and royalties.